Initiate

Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Retrieved on: 
星期五, 十一月 5, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Genetics, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Safety, Syros, G&A, Private Securities Litigation Reform Act, Investor, Director, Venetoclax, Leadership, Clinical trial, Government, Lymphatic system, Security (finance), Initiate, Congress, Compte rendu, Roche, Gene, Acute myeloid leukemia, Freedom, COVID-19, Workforce, GBT, ID, Annual report, BTK, RARA, Twitter, Mantle cell lymphoma, Board, APL, U.S. Securities and Exchange Commission, Research, Genome, Azacitidine, CDK7, LinkedIn, SD, Acute promyelocytic leukemia, BRAF, Pharmacokinetics, Webcast, Pancreatic cancer, Marketing, Patient, Arsenic trioxide, Medical device, Pharmaceutical industry, Medical imaging

Initiate expansion cohort of our SY-5609 trial in combination with chemotherapy in second-line pancreatic cancer in the fourth quarter of 2021.

Key Points: 
  • Initiate expansion cohort of our SY-5609 trial in combination with chemotherapy in second-line pancreatic cancer in the fourth quarter of 2021.
  • Research and development expenses were $27.3 million for the third quarter of 2021, as compared to $17.7 million for the third quarter of 2020.
  • General and administrative (G&A) expenses were $5.3 million for the third quarter of 2021, as compared to $5.2 million for the third quarter of 2020.
  • ET to discuss third quarter 2021 financial results and provide a corporate update.

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

Retrieved on: 
星期三, 十一月 3, 2021
MRI, NPI, Disease, Degenerative disease, Pathology, NIH, CNS, Ovarian cancer, Cerebrospinal fluid, CSF, Â, Natural killer T cell, Clinical trial, Biomarker, COVID-19, Program, ATM, GLOBE, Phase, Biology, TRD, EUA, White matter, APOE4, CDR, Cytokine release syndrome, ADAS, Acceleration, Apolipoprotein E, MDS, Neurodegeneration, Proteome, Goal attainment scaling, Patient, Process control block, Early, Initiate, NASDAQ, FDA, Neuroinflammation, Remyelination, Mortality, Conference, Cognition, NK, Research, MCI, Pharmaceutical industry, Medical device, Medical imaging, Cryptocurrency, Animal

BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Financial Results for the Third Quarter Ended September 30, 2021:
    Net loss attributable to common stockholders for the quarter ended September 30, 2021 was approximately $9.5 million, compared to approximately $4.7 million for the quarter ended September 30, 2020.
  • Research and development expense totaled approximately $6.5 million for the quarter ended September 30, 2021, compared to approximately $2.4 million during the quarter ended September 30, 2020.
  • General and administrative expense was approximately $2.5 million for the quarter ended September 30, 2021, compared to approximately $2.5 million during the quarter ended September 30, 2020.
  • As of September 30, 2021, the Company had cash and cash equivalents of approximately $84.5 million.

Afinis Interoperability Standards Releases New APIs for Account Ownership Validation and Payment Initiation

Retrieved on: 
星期三, 十一月 3, 2021
Efficiency, ACH Network, API Standard 682, Organization, Initiate, ACH, Accreditation, API, Ownership, Education, Cryptocurrency, Bank

HERNDON, Va., Nov. 3, 2021 /PRNewswire/ --Nacha's Afinis Interoperability Standards announced today it has released two APIs to assist financial institutions' business clients with account ownership validation and with payment initiation.

Key Points: 
  • HERNDON, Va., Nov. 3, 2021 /PRNewswire/ --Nacha's Afinis Interoperability Standards announced today it has released two APIs to assist financial institutions' business clients with account ownership validation and with payment initiation.
  • Afinis is a membership-based organization that focuses on the rapid delivery of APIs and other financial services standards across the U.S. and globally.
  • The new APIs are:
    Account Validation Plus Name: validates the owner of an account, as well as the accuracy of the routing and account number.
  • These two APIs are the newest additions to the suite of API standards published by Afinis and adopted by developers.

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

Retrieved on: 
星期三, 十一月 3, 2021
Exposition, Pyruvate kinase deficiency, PDUFA, ASH, Private Securities Litigation Reform Act, Communication, Â, Marketing, Research and development, COVID-19, R, GLOBE, Research, Thalassemia, Host, File, Food, ID, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Income, Risk, NDA, Administration, MAA, Goal, Sickle Cell Disease Association of America, EMA, Caregiver, SEC, Macrocytic anemia, Growth, PKR, Sale, General officer, Society, Board of directors, Priority review, Sickle cell disease, Prescription Drug User Fee Act, Patient, Initiate, NASDAQ, SG, FDA, Investor, Review, Patent, RISE, U.S. Securities and Exchange Commission, Pyruvate kinase, Director, Treatment, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported business highlights and financial results for the third quarter ended Sept. 30, 2021.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for continuing operations were$64.0 million for the third quarter of 2021 compared to$51.9 millionfor the third quarter of 2020.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses for continuing operations were$27.2 millionfor the third quarter of 2021 compared to $28.3 million for the third quarter of 2020.
  • Net Loss: Net loss was$88.8 million for the third quarter of 2021 compared to a net loss of$99.0 millionfor the third quarter of 2020.
  • Agios will host a conference call and live webcast with slides today at8:00 a.m. ETto discuss third quarter 2021 financial results and recent business activities.

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 十一月 3, 2021
Everolimus, Breast cancer, Mutation, Research, Technology, Bayer, AR, Security (finance), U.S. Securities and Exchange Commission, Patient, Insurance, Initiate, State Administrative Expenses, Completeness, Genentech, Exercise, Marketing, Man, Fulvestrant, ER, Development, GLOBE, Administration, ARVN, ASCO, Pharmaceutical industry

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Research and Development Expenses: Research and development expenses were $40.6 million for the quarter ended September 30, 2021, as compared with $30.0 million for the quarter ended September 30, 2020.
  • Revenues: Revenues were $9.3 million for the quarter ended September 30, 2021 as compared to $7.6 million for the quarter ended September 30, 2020.
  • Net Loss: Net loss was $46.8 million for the quarter ended September 30, 2021, as compared with $30.8 million for the quarter ended September 30, 2020.

DGAP-News: IGP Advantag AG: Quirin Privatbank Equity Research, in its initial study, also sees considerable upside potential in the IGP share - Rating: Buy, target price: EUR 3.75

Retrieved on: 
星期一, 十月 25, 2021
DCF, EBITDA, Federal republic, ISIN, Architecture, IGP, Initiate, EUR, Software, Policy by press release, WKN, BIM, Growth, Ex parte Quirin, Competitive advantage, Health, Research, Building information modeling, AEC, Education, Security (finance), Risk management

IGP Advantag AG: Quirin Privatbank Equity Research, in its initial study, also sees considerable upside potential in the IGP share - Rating: Buy, target price: EUR 3.75

Key Points: 
  • IGP Advantag AG: Quirin Privatbank Equity Research, in its initial study, also sees considerable upside potential in the IGP share - Rating: Buy, target price: EUR 3.75
    The issuer is solely responsible for the content of this announcement.
  • IGP Advantag AG: Quirin Privatbank Equity Research, in its initial study, also sees considerable upside potential in the IGP share - Rating: Buy, target price: EUR 3.75
    Berlin, 25.10.2021.
  • IGP Advantag AG (WKN A1EWVR / ISIN DE000A1EWVR2) has now been covered by a second well-known investment analysis company: Quirin Privatbank Equity Research.
  • In its published initial study, the Quirin analysts see considerable upside potential in the IGP share.

Global Wind Industry manifesto calls on governments to "get serious" ahead of COP26 and support public and private initiatives to secure the energy transition

Retrieved on: 
星期一, 十月 18, 2021
Organization, Technology, Green Investment Group, Global Wind Energy Council, Industry, Nationally Determined Contributions, SSE, Private sector, EDP, Climate change, Growth, Eddie O'Connor (businessman), Coal, IRENA, IEA, Initiate, DNV, Iberdrola Renovables, Policy, Insurance, Manifesto, GWEC, COP26, Siemens Gamesa, Vestas, ENEL, Wind, Carbon, Commit, Climate, CO2, Renewable energy

LONDON, Oct. 18, 2021 /PRNewswire/ -- The wind energy sector has released a manifesto at the BNEF London summit calling on governments to "get serious" about the energy transition and work with the private sector to rapidly scale up wind and renewable energy installations.

Key Points: 
  • The wind industry has the tools available to achieve ambitious targets like a fourfold increase in the amount of wind energy deployed globally - this manifesto asks governments to help the wind industry get there.
  • LONDON, Oct. 18, 2021 /PRNewswire/ -- The wind energy sector has released a manifesto at the BNEF London summit calling on governments to "get serious" about the energy transition and work with the private sector to rapidly scale up wind and renewable energy installations.
  • Wind energy is one of the fastest growing energy sources in the world, with a record 93GW of installations in 2020.
  • More than 90 of the world's leading wind energy companies, led by the Global Wind Energy Council (GWEC), including manufacturers, supply chain actors, investors and industry bodies from around the world have united to support this Manifesto.

Global Wind Industry manifesto calls on governments to "get serious" ahead of COP26 and support public and private initiatives to secure the energy transition

Retrieved on: 
星期一, 十月 18, 2021
Organization, Technology, Green Investment Group, Global Wind Energy Council, Industry, Nationally Determined Contributions, SSE, Private sector, EDP, Climate change, Growth, Eddie O'Connor (businessman), Coal, IRENA, IEA, Initiate, DNV, Iberdrola Renovables, Policy, Insurance, Manifesto, GWEC, COP26, Siemens Gamesa, Vestas, ENEL, Wind, Carbon, Commit, Climate, CO2, Renewable energy

LONDON, Oct. 18, 2021 /PRNewswire/ -- The wind energy sector has released a manifesto at the BNEF London summit calling on governments to "get serious" about the energy transition and work with the private sector to rapidly scale up wind and renewable energy installations.

Key Points: 
  • The wind industry has the tools available to achieve ambitious targets like a fourfold increase in the amount of wind energy deployed globally - this manifesto asks governments to help the wind industry get there.
  • LONDON, Oct. 18, 2021 /PRNewswire/ -- The wind energy sector has released a manifesto at the BNEF London summit calling on governments to "get serious" about the energy transition and work with the private sector to rapidly scale up wind and renewable energy installations.
  • Wind energy is one of the fastest growing energy sources in the world, with a record 93GW of installations in 2020.
  • More than 90 of the world's leading wind energy companies, led by the Global Wind Energy Council (GWEC), including manufacturers, supply chain actors, investors and industry bodies from around the world have united to support this Manifesto.

Arlo Offers Comprehensive Third-Party Compatibility With Amazon, Apple, Google, Samsung, And Others For Seamless Smart Home Security Experience

Retrieved on: 
星期二, 八月 31, 2021
Trigger, Industry, Ecosystem, Siri, Company, Arlo Technologies, Ultra, Private Securities Litigation Reform Act, LTE, HomeKit, Wi-Fi, Legislation, Privacy, Human voice, Software, U.S. Securities and Exchange Commission, Human, IPhone, BT Smart Hub, Engineering, Mission statement, Google Nest (smart speakers), IPad, IFTTT, Compte rendu, Amazon Alexa, Apple Watch, Initiate, SVP, Time, Television, CIO, Tablet, NYSE, Risk, Multimedia, Apple TV, Integration, Fire, SAN, Mac, Alexa, Home, Eye, Apple, PIN, SmartThings, Samsung, Annual report, Technology, Security (finance), Mobile phone, Online shopping, Instrumentation, Satellite navigation device, Cassette tape

Robust partner integrations provide Arlo users with a seamless experience between their Arlo smart home security system and smart home ecosystem.

Key Points: 
  • Robust partner integrations provide Arlo users with a seamless experience between their Arlo smart home security system and smart home ecosystem.
  • Arlo users benefit from more efficient, integrated access to popular Arlo features no matter which third-party smart home platform they have at home.
  • Initiate two-way talk through compatible Echo and Fire TV devices to Arlo security cameras or video doorbells.
  • Receive proactive updates for seamless integration any time you add a new Arlo camera, base station, or doorbell to an already-linked Amazon account.

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
星期四, 八月 19, 2021
Company, Terminology, Private Securities Litigation Reform Act, Therapy, Cancer, U.S. Securities and Exchange Commission, Neoplasm, GLOBE, SEC, Phase, Organic acid, Security (finance), Bevacizumab, Protide, Cisplatin, Initiate, NDA, Forward-looking statement, Oxaliplatin, NASDAQ, Goal, Patient, Report, Phases of clinical research, Colorectal cancer, Â, COVID-19, NCNA, Irinotecan, Pharmaceutical industry, Medical imaging, Beauty salon

EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of June 30, 2021, NuCana had cash and cash equivalents of 73.4 million compared to 78.6 million at March 31, 2021 and 87.4 million as of December 31, 2020.
  • Basic and diluted loss per share was 0.17 for the quarter ended June 30, 2021, as compared to 0.19 per share for quarter ended June 30, 2020.
  • It has been a productive first half of 2021 withour release of important non-clinical and clinical data announcements.